Oric Pharmaceuticals
ORIC
Market cap $946M

11.10 USD

-0.35

3.06%

At close Jul 11, 4:00 PM EDT

After hours

11.10

+0.00

0.00%

1 day

-3.06%

5 days

2.97%

1 month

18.21%

3 months

125.61%

6 months

29.07%

Year to date

34.38%

1 year

15.63%

5 years

-54.32%

10 years

-56.93%

About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Employees: 122

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

196% more call options, than puts

Call options by funds: $74K | Put options by funds: $25K

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

26% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 39

11% more funds holding

Funds holding: 129 [Q4 2024] → 143 (+14) [Q1 2025]

4.11% more ownership

Funds ownership: 107.4% [Q4 2024] → 111.52% (+4.11%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 5 (+0) [Q1 2025]

28% less capital invested

Capital invested by funds: $612M [Q4 2024] → $442M (-$170M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

8%

upside

Avg. target

$16.33

47%

upside

High target

$22

98%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Ladenburg Thalmann Kevin DeGeeter	35%upside $15	Buy Initiated	8 Jul 2025
HC Wainwright & Co. Robert Burns	98%upside $22	Buy Maintained	9 May 2025
Oppenheimer Matthew Biegler	8%upside $12	Outperform Maintained	6 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ORIC published over the past 30 days

Zacks Investment Research

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Oric Pharmaceuticals (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy

Zacks Investment Research

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

The consensus price target hints at a 105% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect?

Zacks Investment Research

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

Does Oric Pharmaceuticals, Inc. (ORIC) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now?

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the “Grant Date”), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know

Zacks Investment Research

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

ORIC Pharmaceuticals Inc. ORIC released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing

See News Rankings

Charts implemented using Lightweight Charts™